Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma cells by reducing intracellular cisplatin accumulation

Molecular Pharmacology

Volumn 79, Issue 3, 2011, Pages 608-617

  Yu, Le ^a   Chen, Minghui ^a   Li, Zhijie ^b   Wen, Jing ^c   Fu, Jianhua ^c   Guo, Dan ^a   Jiang, Yong ^a   Wu, Shuguang ^a   Cho, Chi Hin ^b   Liu, Shuwen ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CARRIER PROTEINS AND BINDING PROTEINS; CELECOXIB; CISPLATIN; COPPER TRANSPORTER 1; CYCLOOXYGENASE 2; INDOMETACIN; NIMESULIDE; PROSTAGLANDIN E2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CARCINOMA CELL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CYTOTOXICITY; DNA ADDUCT; DOWN REGULATION; DRUG ACCUMULATION; DRUG ANTAGONISM; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; CYCLOOXYGENASE 2 INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PYRAZOLES; SULFONAMIDES;

EID: 79951996444     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.069393     Document Type: Article

References (38)

1. Bijman MN, Hermelink CA, van Berkel MP, Laan AC, Janmaat ML, Peters GJ, and Boven E (2008) Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem Pharmacol 75:427-437. (Pubitemid 350298473)
2. Blair BG, Larson CA, Safaei R, and Howell SB (2009) Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. Clin Cancer Res 15:4312-4321.
3. Corley DA, Kerlikowske K, Verma R, and Buffler P (2003) Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124:47-56. (Pubitemid 36055338)
4. Dawson SJ, Michael M, Biagi J, Foo KF, Jefford M, Ngan SY, Leong T, Hui A, Milner AD, Thomas RJ, et al. (2007) A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs 25:123-129. (Pubitemid 46020870)
5. Ekman S, Dreilich M, Lennartsson J, Wallner B, Brattström D, Sundbom M, and Bergqvist M (2008) Esophageal cancer: current and emerging therapy modalities. Expert Rev Anticancer Ther 8:1433-1448.
6. Goldberg Y, Nassif II, Pittas A, Tsai LL, Dynlacht BD, Rigas B, and Shiff SJ (1996) The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12:893-901. (Pubitemid 26072275)
7. Grösch S, Tegeder I, Niederberger E, Bräutigam L, and Geisslinger G (2001) COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15:2742-2744.
8. Hall MD, Okabe M, Shen DW, Liang XJ, and Gottesman MM (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48:495-535. (Pubitemid 351738162)
9. Hashitani S, Urade M, Nishimura N, Maeda T, Takaoka K, Noguchi K, and Sakurai K (2003) Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol 23:665-672.
10. Holzer AK and Howell SB (2006) The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 66:10944-10952. (Pubitemid 44876993)
11. Holzer AK, Katano K, Klomp LW, and Howell SB (2004a) Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 10:6744-6749. (Pubitemid 39346572)
12. Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, and Howell SB (2004b) The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66:817-823. (Pubitemid 39319453)
13. Howell SB, Safaei R, Larson CA, and Sailor MJ (2010) Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 77:887-894.
14. Hu Y, Lam KY, Wan TS, Fang W, Ma ES, Chan LC, and Srivastava G (2000) Establishment and characterization of HKESC-1, a new cancer cell line from human esophageal squamous cell carcinoma. Cancer Genet Cytogenet 118:112-120. (Pubitemid 30169212)
15. Ilson DH (2008) Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res 2:85-92.
16. Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B, and Cavallin-Stahl E (1995) Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol 37:23-31.
17. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, and Tarnawski AS (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5:1418-1423.
18. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573-584.
19. Kilic A, Schuchert MJ, Luketich JD, Landreneau RJ, and El-Hefnawy T (2009) Efficacy of signal pathway inhibitors alone and in combination with cisplatin varies between human non-small cell lung cancer lines. J Surg Res 154:9-12.
20. Kim SH, Kim SH, Song YC, and Song YS (2009) Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase. Ann NY Acad Sci 1171:635-641.
21. Larson CA, Blair BG, Safaei R, and Howell SB (2009) The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol 75:324-330.
22. Li WZ, Wang XY, Li ZG, Zhang JH, and Ding YQ (2010) Celecoxib enhances the inhibitory effect of cisplatin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro. J Oral Pathol Med 39:579-584.
23. Martin LP, Hamilton TC, and Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14:1291-1295. (Pubitemid 351413906)
24. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, and Seibert K (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311. (Pubitemid 30151999)
25. Mizutani Y, Nakanishi H, Li YN, Sato N, Kawauchi A, and Miki T (2004) Enhanced sensitivity of bladder cancer cells to cisplatin mediated cytotoxicity and apoptosis in vitro and in vivo by the selective cyclooxygenase-2 inhibitor JTE-522. J Urol 172:1474-1479. (Pubitemid 39249752)
26. Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhofer C, Bräutigam L, Grösch S, and Geisslinger G (2001) Celecoxib loses its antiinflammatory efficacy at high doses through activation of NF-kappaB. FASEB J 15:1622-1624.
27. Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, and Howell SB (2004) Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10:4661-4669. (Pubitemid 38955516)
28. Shao J, Fujiwara T, Kadowaki Y, Fukazawa T, Waku T, Itoshima T, Yamatsuji T, Nishizaki M, Roth JA, and Tanaka N (2000) Overexpression of the wild-type P53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 19:726-736. (Pubitemid 30107703)
29. Siersema PD (2008) Esophageal cancer. Gastroenterol Clin North Am 37:943-964.
30. Stoner GD, Qin H, Chen T, Carlton PS, Rose ME, Aziz RM, and Dixit R (2005) The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine- induced rat esophageal tumorigenesis. Carcinogenesis 26:1590-1595. (Pubitemid 41236052)
31. Sugiura T, Saikawa Y, Kubota T, Suganuma K, Otani Y, Watanabe M, Kumai K, and Kitajima M (2003) Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo. In Vivo 17:229-233. (Pubitemid 36958111)
32. Takahashi T, Kozaki K, Yatabe Y, Achiwa H, and Hida T (2002) Increased expression of COX-2 in the development of human lung cancers. J Environ Pathol Toxicol Oncol 21:177-181. (Pubitemid 34655038)
33. Takatori H, Natsugoe S, Okumura H, Matsumoto M, Ishigami S, Owaki T, and Aikou T (2005) Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma. Oncol Rep 13:697-701.
34. Tew WP, Kelsen DP, and Ilson DH (2005) Targeted therapies for esophageal cancer. Oncologist 10:590-601. (Pubitemid 41429122)
35. Toshimitsu H, Hashimoto K, Tangoku A, Iizuka N, Yamamoto K, Kawauchi S, Oga A, Furuya T, Oka M, and Sasaki K (2004) Molecular signature linked to acquired resistance to cisplatin in esophageal cancer cells. Cancer Lett 211:69-78. (Pubitemid 38759770)
36. Xi H, Baldus SE, Warnecke-Eberz U, Brabender J, Neiss S, Metzger R, Ling FC, Dienes HP, Bollschweiler E, Moenig S, et al. (2005) High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 11:8341-8347. (Pubitemid 41746946)
37. Yu L, Wu WK, Li ZJ, Liu QC, Li HT, Wu YC, and Cho CH (2009) Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1- yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity. Mol Pharmacol 75:1364-1373.
38. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, and Schrör K (1999) Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59:198-204. (Pubitemid 29062978)